Endeavor Clinical Trials

The trials here

What the 28 trials at this site are about, from their registry records.

Conditions

• Obesity16 trials
• Type 2 diabetes10 trials
• Fatty liver disease (MASLD/MASH)4 trials
• Chronic kidney disease2 trials
• Familial hypercholesterolaemia2 trials
• Gout2 trials
• Osteoarthritis2 trials
• Asthma1 trial
• Coronary artery disease1 trial
• Deep vein thrombosis and pulmonary embolism1 trial
• Heart failure1 trial
• High blood pressure1 trial
• and 4 more

Phase

• Phase 212 trials
• Phase 17 trials
• Phase 37 trials
• Phase 1/21 trial

Status

• Completed13 trials
• Active, not recruiting6 trials
• Recruiting6 trials
• Not yet recruiting1 trial
• Terminated1 trial
• Withdrawn1 trial

Lead sponsor

• Eli Lilly and Company13 trials
• Boehringer Ingelheim2 trials
• Regeneron Pharmaceuticals2 trials
• Alveus Therapeutics, Inc.1 trial
• Amgen1 trial
• and 9 more

Running trials

• Not yet recruiting

  A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes

  NCT07890376· Phase 2· Eli Lilly and Company· Source

  Contact: Nitendra Agarwal (principal investigator)

• Active, not recruiting

  A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia

  NCT07477704· Phase 2· Regeneron Pharmaceuticals· Source

• Recruiting

  A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

  NCT07589608· Phase 2· Eli Lilly and Company· Source

  Contact: Nitendra Agarwal (principal investigator)

• Recruiting

  A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

  NCT07392190· Phase 3· Eli Lilly and Company· Source

  Contact: Nitendra Agarwal (principal investigator)

• Recruiting

  Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

  NCT07353931· Phase 3· Eli Lilly and Company· Source

  Contact: Nitendra Agarwal (principal investigator)

• Active, not recruiting

  Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D

  NCT07399678· Phase 1· Alveus Therapeutics, Inc.· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Recruiting

  Evaluation of Non-Invasive Tests for Metabolic Liver Disease

  NCT07122700· Foundation for the National Institutes of Health· Source

  Contact: Emanuel De Noia, MD

• Active, not recruiting

  53-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 With Mild to Severe Tibio-Femoral Osteoarthritis of the Knee

  NCT06865079· Phase 2· OrthoTrophix, Inc· Source

• Active, not recruiting

  A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma

  NCT06637371· Phase 1· Amgen· Source

• Active, not recruiting

  The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

  NCT06383390· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

  NCT06143956· Phase 2· Eli Lilly and Company· Source

  Contact: Nitendra Agarwal (principal investigator)

• Active, not recruiting

  Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

  NCT05030428· Phase 3· Novartis Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity5 recruiting
• Type 2 diabetes4 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• High blood pressure1 recruiting
• Liver cirrhosis1 recruiting
• Osteoarthritis1 recruiting

Closed trials

• Recruiting

  REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants

  NCT07213778· Phase 3· Regeneron Pharmaceuticals· Source

  Contact: Clinical Trials Administrator

• Terminated

  A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes

  NCT07030868· Phase 2· Eli Lilly and Company· Source

• Completed

  A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes

  NCT06945419· Phase 1· Eli Lilly and Company· Source

• Completed

  Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants

  NCT06737042· Phase 2· Gan and Lee Pharmaceuticals, USA· Source

• Completed

  A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight

  NCT06824051· Phase 1· Eli Lilly and Company· Source

• Completed

  A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight

  NCT06683508· Phase 2· Eli Lilly and Company· Source

• Completed

  A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

  NCT06603571· Phase 2· Eli Lilly and Company· Source

• Completed

  A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

  NCT06230523· Phase 2· Eli Lilly and Company· Source

• Completed

  Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia

  NCT06056570· Phase 1/2· Urica Therapeutics Inc.· Source

• Completed

  A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease

  NCT05970640· Phase 1· Boehringer Ingelheim· Source

• Completed

  Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants With CKD and Anemia

  NCT05745883· Phase 1· Disc Medicine, Inc· Source

• Completed

  A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia

  NCT05542264· Phase 1· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source

• Completed

  Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis

  NCT05327127· Phase 2· Kowa Research Institute, Inc.· Source

• Completed

  Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients

  NCT05586958· Phase 3· LG Chem· Source

• Completed

  A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)

  NCT04166773· Phase 2· Eli Lilly and Company· Source